National Cancer Institute et al., 2022-06-14: NCI's PDQ summary states laetrile is not approved in the United States, that it has shown no anticancer activity in human trials, and that hydrogen cyanide release is the proposed mechanism of harm. It also states that no controlled clinical trial of laetrile has ever been conducted.
Laetrile has shown little anticancer activity in animal studies and no anticancer activity in human clinical trials.
Overview, unpaginated web page
National Cancer Institute et al., 2022-06-14: NCI's PDQ summary states laetrile is not approved in the United States, that it has shown no anticancer activity in human trials, and that hydrogen cyanide release is the proposed mechanism of harm. It also states that no controlled clinical trial of laetrile has ever been conducted. Funder/conflicts: n/a (government evidence review; PDQ states it does not represent NCI policy). Comparator: n/a. CAREFUL – the summary contains both halves of the book's sentence: 'No controlled clinical trial of laetrile has ever been conducted' (supports 'no large-scale trials' if read as 'no controlled trial'), yet the same summary reviews the 178-patient NCI/Mayo prospective trial (CHF-01) and the 1978 NCI retrospective review of 68 case reports. Page flags the summary as no longer updated (last update 06/14/2022). Study type: review.
